Population Pharmacokinetics of Unbound Ceftolozane and Tazobactam in Critically Ill Patients without Renal Dysfunction.
ceftolozane
critically ill
dosing
intensive care unit
population pharmacokinetics
tazobactam
Journal
Antimicrobial agents and chemotherapy
ISSN: 1098-6596
Titre abrégé: Antimicrob Agents Chemother
Pays: United States
ID NLM: 0315061
Informations de publication
Date de publication:
10 2019
10 2019
Historique:
received:
21
06
2019
accepted:
20
07
2019
pubmed:
31
7
2019
medline:
4
8
2020
entrez:
31
7
2019
Statut:
epublish
Résumé
Evaluation of dosing regimens for critically ill patients requires pharmacokinetic data in this population. This prospective observational study aimed to describe the population pharmacokinetics of unbound ceftolozane and tazobactam in critically ill patients without renal impairment and to assess the adequacy of recommended dosing regimens for treatment of systemic infections. Patients received 1.5 or 3.0 g ceftolozane-tazobactam according to clinician recommendation. Unbound ceftolozane and tazobactam plasma concentrations were assayed, and data were analyzed with Pmetrics with subsequent Monte Carlo simulations. A two-compartment model adequately described the data from twelve patients. Urinary creatinine clearance (CL
Identifiants
pubmed: 31358583
pii: AAC.01265-19
doi: 10.1128/AAC.01265-19
pmc: PMC6761554
pii:
doi:
Substances chimiques
Anti-Bacterial Agents
0
Cephalosporins
0
ceftolozane, tazobactam drug combination
0
ceftolozane
37A4IES95Q
Tazobactam
SE10G96M8W
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2019 Sime et al.
Références
PLoS One. 2018 Apr 12;13(4):e0195757
pubmed: 29649276
Clin Infect Dis. 2014 Apr;58(8):1072-83
pubmed: 24429437
Antimicrob Agents Chemother. 2017 Feb 23;61(3):
pubmed: 27956431
Diagn Microbiol Infect Dis. 2018 Oct;92(2):158-163
pubmed: 29891184
Crit Care. 2010;14(4):R126
pubmed: 20594297
Eur J Clin Microbiol Infect Dis. 2019 Aug;38(8):1457-1461
pubmed: 31073653
Clin Pharmacokinet. 2011 Feb;50(2):99-110
pubmed: 21142293
Antimicrob Agents Chemother. 2010 Jul;54(7):2974-8
pubmed: 20479205
Clin Infect Dis. 1998 Jan;26(1):1-10; quiz 11-2
pubmed: 9455502
J Infect Chemother. 2019 Mar;25(3):182-191
pubmed: 30528208
Adv Drug Deliv Rev. 2014 Nov 20;77:3-11
pubmed: 25038549
J Clin Pharmacol. 2016 Jan;56(1):56-66
pubmed: 26096377
Lancet Infect Dis. 2014 Jun;14(6):498-509
pubmed: 24768475
Antimicrob Agents Chemother. 2013 Dec;57(12):6165-70
pubmed: 24080664
Antimicrob Agents Chemother. 1994 May;38(5):931-6
pubmed: 8067772
Infection. 2018 Aug;46(4):461-468
pubmed: 29594953
J Pharm Biomed Anal. 2019 Jan 30;163:34-38
pubmed: 30278324
Expert Rev Anti Infect Ther. 2018 May;16(5):367-368
pubmed: 29727213
Antimicrob Agents Chemother. 2005 Dec;49(12):4920-7
pubmed: 16304153
J Pharm Sci. 2013 Sep;102(9):2953-94
pubmed: 23798314
Antimicrob Agents Chemother. 2013 Apr;57(4):1577-82
pubmed: 23274659
Clin Case Rep. 2018 May 28;6(7):1308-1312
pubmed: 29988582
Blood Purif. 2017;44(1):16-23
pubmed: 28237981
J Antimicrob Chemother. 2012 Oct;67(10):2463-9
pubmed: 22773741
BMC Anesthesiol. 2011 Feb 20;11:3
pubmed: 21333028
J Antimicrob Chemother. 2014 May;69(5):1416-23
pubmed: 24443514
Crit Care Med. 2008 Aug;36(8):2433-40
pubmed: 18596628
Crit Care Med. 2014 Mar;42(3):520-7
pubmed: 24201175
Antimicrob Agents Chemother. 2014 Oct;58(10):6311-4
pubmed: 25092700
Antimicrob Agents Chemother. 2019 May 24;63(6):
pubmed: 30962340
Infect Dis Ther. 2017 Mar;6(1):137-148
pubmed: 28013453
Expert Rev Anti Infect Ther. 2018 Apr;16(4):307-320
pubmed: 29493397
Ann Pharmacother. 2017 Aug;51(8):715-716
pubmed: 28351154
Clin Microbiol Infect. 2015 Oct;21(10):886-93
pubmed: 25980350
Antimicrob Agents Chemother. 2015;59(6):3373-6
pubmed: 25824214
Int J Antimicrob Agents. 2014 Jun;43(6):533-9
pubmed: 24856078